A federal jury in Delaware has found that Amgen and its acquired Teneobio willfully infringed on an antibody patent held by Harbour Antibodies, a Dutch subsidiary of China’s Harbour BioMed.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
